Principal Consultant & Client Operations Expert
Pharmetheus AB
Jakob Ribbing is a Principal MIDD Consultant at Pharmetheus, born in Sweden 1975. He obtained his M.Sc. in pharmacy and his Ph.D. from the University of Uppsala, with the Ph.D. thesis entitled “Covariate Model Building in Nonlinear Mixed Effects Models”. Following this Jakob joined Pfizer in 2007, as pharmacometrician based in Sandwich, UK. In 2009 Jakob became the subject-matter expert for Allergy and Respiratory pharmacometrics. In this role Jakob provided pharmacometrics support for up to ten compounds in clinical development at the same time, interacting with the clinical and pre-clinical teams and governance bodies, as well as many external pharmacometrics consultants. In 2010 Jakob moved to Sweden, continuing to support Pfizer Allergy and Respiratory for another four years, after which he joined Pharmetheus in 2014.
During his time at Pharmetheus, Jakob has worked in different roles, e.g. hands-on pharmacometrics modelling, project lead, scientific advisor and with regulatory interactions, collaborating with more than 50 different clients. The projects have spanned from study design to pharmacometric analysis and simulation and from pre-clinical to post-marketing phases. During his initial years at Pharmetheus Jakob authored many submission-ready population-modelling reports, of which most have been submitted to regulatory agencies, e.g. FDA, EMA, PMDA and NMPA. While keeping a focus on the indications related to Allergy and Respiratory (e.g. Asthma, COPD, IPF/ILDs, AD, UC/CD and several other inflammatory diseases), Jakob has also worked in many other therapeutic areas, including Oncology, Neuroscience, Diabetes, and Bleeding disorders.
Jakob has extensive experience using nonlinear-mixed effects models with MIDD applications spanning all the way from setting targets for and making decision on interim/trial/program success (go vs. no-go, PoP/PoM/PoC declaration, dose selection, etc.) to pharmacoeconomic simulations of real-life outcomes. These applications often involved translation/extrapolation across endpoints and populations as well as analysis of both individual-level (internal-trial) data and aggregate-level data.
Disclosure information not submitted.
Saturday, October 18, 2025
2:30 PM - 2:45 PM MDT